JP2022538215A - 経口カプセルおよびその調製方法 - Google Patents

経口カプセルおよびその調製方法 Download PDF

Info

Publication number
JP2022538215A
JP2022538215A JP2021572442A JP2021572442A JP2022538215A JP 2022538215 A JP2022538215 A JP 2022538215A JP 2021572442 A JP2021572442 A JP 2021572442A JP 2021572442 A JP2021572442 A JP 2021572442A JP 2022538215 A JP2022538215 A JP 2022538215A
Authority
JP
Japan
Prior art keywords
oral capsule
oral
capsule
zanubrutinib
rpm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021572442A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538215A5 (https=
Inventor
ヤン、イーピン
グオ、ユアンジン
Original Assignee
ベイジーン スウィッツァーランド ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベイジーン スウィッツァーランド ゲーエムベーハー filed Critical ベイジーン スウィッツァーランド ゲーエムベーハー
Publication of JP2022538215A publication Critical patent/JP2022538215A/ja
Publication of JP2022538215A5 publication Critical patent/JP2022538215A5/ja
Priority to JP2025106604A priority Critical patent/JP2025123534A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021572442A 2019-06-10 2020-06-10 経口カプセルおよびその調製方法 Withdrawn JP2022538215A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025106604A JP2025123534A (ja) 2019-06-10 2025-06-24 経口カプセルおよびその調製方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019090543 2019-06-10
CNPCT/CN2019/090543 2019-06-10
PCT/CN2020/095353 WO2020249002A1 (zh) 2019-06-10 2020-06-10 口服胶囊剂及其制备方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025106604A Division JP2025123534A (ja) 2019-06-10 2025-06-24 経口カプセルおよびその調製方法

Publications (2)

Publication Number Publication Date
JP2022538215A true JP2022538215A (ja) 2022-09-01
JP2022538215A5 JP2022538215A5 (https=) 2023-06-20

Family

ID=73780902

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021572442A Withdrawn JP2022538215A (ja) 2019-06-10 2020-06-10 経口カプセルおよびその調製方法
JP2025106604A Pending JP2025123534A (ja) 2019-06-10 2025-06-24 経口カプセルおよびその調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025106604A Pending JP2025123534A (ja) 2019-06-10 2025-06-24 経口カプセルおよびその調製方法

Country Status (6)

Country Link
US (2) US20220241285A1 (https=)
EP (1) EP3981400A4 (https=)
JP (2) JP2022538215A (https=)
CN (1) CN113950327A (https=)
TW (1) TW202112369A (https=)
WO (1) WO2020249002A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
WO2018033853A2 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3645569A4 (en) 2017-06-26 2021-03-24 BeiGene, Ltd. IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
WO2019108795A1 (en) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors
US20220249491A1 (en) 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN115212115A (zh) * 2021-09-27 2022-10-21 百济神州(苏州)生物科技有限公司 泽布替尼的鼻饲给药
CN119699478B (zh) * 2024-12-24 2025-12-12 衡睿(广东)生物科技有限公司 一种高油脂含量的胶囊制剂及其制备方法
CN119818691B (zh) * 2025-03-18 2025-08-05 宁波美诺华天康药业有限公司 一种含有伊布替尼的药物组合物及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521273A (ja) * 2013-04-25 2016-07-21 ベイジーン，リミテッド タンパク質キナーゼ阻害剤としての縮合複素環化合物
US20190169201A1 (en) * 2016-08-16 2019-06-06 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717745B2 (en) * 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN112165939A (zh) * 2018-03-21 2021-01-01 梅制药公司 联合疗法
US10688050B1 (en) * 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521273A (ja) * 2013-04-25 2016-07-21 ベイジーン，リミテッド タンパク質キナーゼ阻害剤としての縮合複素環化合物
US20190169201A1 (en) * 2016-08-16 2019-06-06 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof

Also Published As

Publication number Publication date
TW202112369A (zh) 2021-04-01
JP2025123534A (ja) 2025-08-22
WO2020249002A1 (zh) 2020-12-17
CN113950327A (zh) 2022-01-18
EP3981400A4 (en) 2023-07-12
US20220241285A1 (en) 2022-08-04
US20230149411A1 (en) 2023-05-18
EP3981400A1 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
JP2022538215A (ja) 経口カプセルおよびその調製方法
JP7550393B2 (ja) 低分子ｅｇｆｒ阻害剤を含む医薬組成物及びその製造方法
US12233069B2 (en) Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor
JP7437460B2 (ja) Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
JP2021512117A (ja) 嚢胞性線維症を処置するための医薬組成物
CA2744142A1 (en) Directly compressible granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN112220770B (zh) 司来帕格的药物组合物及其制备方法
JP2008531737A (ja) アリピプラゾールの湿式造粒医薬組成物
WO2011010324A1 (en) Oral pharmaceutical composition of rasagiline and process for preparing thereof
CN110420192B (zh) 一种单硝酸异山梨酯缓释片及制备方法
KR20110086741A (ko) 직접 압축가능한 고 기능성 과립상 이염기성 인산칼슘 기재 공-가공된 부형제
EP2365798A2 (en) Wet granulation of tenofovir, emtricitabine and efavirenz
JP2020510027A (ja) ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤
EP2050436A1 (en) Pharmaceutical composition containing dutasteride
NZ719865A (en) A pharmaceutical dosage form produced from the wet granulation of 3-(2,6-dichloro-3,5- dimethoxy-phenyl)-1-{ 6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl} -1-methylurea
CN121038782A (zh) 具有改善的生物利用度的仑伐替尼组合物
CN103405394A (zh) 一种酒石酸美托洛尔缓释片及其制备方法
HK40066903A (en) Oral capsule and preparation method therefor
WO2022062096A1 (zh) 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物
CN112057432A (zh) 口服胶囊剂及其制备方法
JP6293850B1 (ja) 医薬組成物におけるアジルサルタンの速やかな溶出性を維持し、かつ安定化する方法
CN111249241A (zh) 一种含有难溶性噻吩并吡啶组合物的固体制剂及制备方法
CN101505734A (zh) 用于制备具有高储存稳定性的普拉克索二盐酸盐片剂的方法
WO2026003296A1 (en) Solid oral formulation of mono-amine re-uptake inhibitor
CN121668126A (zh) 一种罗沙司他胶囊的制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230609

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250107

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250624

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250707